These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Acute nonlymphocytic leukemia after thiotepa instillation into the bladder: report of 2 cases and review of the literature. Silberberg JM; Zarrabi MH J Urol; 1987 Aug; 138(2):402-3. PubMed ID: 3110436 [TBL] [Abstract][Full Text] [Related]
5. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group. Debruyne FM; van der Meijden AP; Franssen MP Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556 [No Abstract] [Full Text] [Related]
6. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. Drago PC; Badalament RA; Lucas J; Drago JR J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794 [TBL] [Abstract][Full Text] [Related]
7. Rationale for intensive intravesical chemotherapy for superficial bladder cancer. Soloway MS J Urol; 1980 Apr; 123(4):461-6. PubMed ID: 6767860 [No Abstract] [Full Text] [Related]
8. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients. Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488 [TBL] [Abstract][Full Text] [Related]
10. The management of superficial bladder cancer. Soloway MS Cancer; 1980 Apr; 45(7 Suppl):1856-65. PubMed ID: 6768441 [No Abstract] [Full Text] [Related]
11. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa. Mobley WC; Loening SA; Narayana AS; Culp DA Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555 [TBL] [Abstract][Full Text] [Related]
12. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. Zincke H; Benson RC; Hilton JF; Taylor WF J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685 [TBL] [Abstract][Full Text] [Related]
13. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? Droller MJ; Walsh PC J Urol; 1985 Dec; 134(6):1115-7. PubMed ID: 3932686 [TBL] [Abstract][Full Text] [Related]
17. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder. Hardeman SW; Perry A; Soloway MS J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420 [TBL] [Abstract][Full Text] [Related]
18. Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa. Wood DP; Streem SB; Levin HS J Urol; 1988 Jan; 139(1):130-1. PubMed ID: 3121867 [TBL] [Abstract][Full Text] [Related]
19. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer. Baker WC; Russo MA; deVere White RW Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739 [TBL] [Abstract][Full Text] [Related]
20. Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor. Hu KN; Kim A; Khan AS; Soroff H; Gonder M Cancer; 1985 Apr; 55(8):1654-8. PubMed ID: 3156664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]